Relay Therapeutics, Inc. SEC Filings

The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership in Relay Therapeutics Inc Common Stock. The filing states that, following an internal realignment effective January 12, 2026, the reporting entities disaggregated holdings and report beneficial ownership of 0 shares (0%) for this class. The filing lists Vanguard's address and explains that certain subsidiaries now report separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim as Head of Global Fund Administration on March 27, 2026.

Relay Therapeutics reports that Perceptive Life Sciences Master Fund, Perceptive Advisors LLC and Joseph Edelman each beneficially own 9,404,725 shares of Common Stock, representing 5.3% of the class.

Ownership is shown as shared voting and dispositive power for 9,404,725 shares. The filing cites 178,725,809 shares outstanding as of February 20, 2026 as the basis for percentage calculation.

Relay Therapeutics reported new Phase 1/2 data for its PI3Kα inhibitor zovegalisib combined with fulvestrant at the recommended Phase 3 dose of 400mg twice daily with food in PI3Kα‑mutated, HR+/HER2- metastatic breast cancer.

Among 57 efficacy-evaluable patients as of the January 13, 2026 cut-off, median progression-free survival was 11.1 months, with similar outcomes for kinase and non‑kinase mutations. In 35 patients with measurable disease, the confirmed objective response rate was 43%, and 52% in second-line-only patients. The regimen was generally well tolerated in 60 treated patients, with mostly low‑grade, manageable adverse events, a hyperglycemia profile dominated by Grade 1 events, and only four discontinuations due to treatment-related side effects. These data support use of the 400mg fed dose in the ongoing global Phase 3 ReDiscover‑2 trial, for which the combination has FDA Breakthrough Therapy designation.

Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported an open-market sale of 17,717 shares of common stock on March 9, 2026 at a weighted average price of $10.06 per share. The trades were executed at prices ranging from $9.77 to $10.35 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on October 30, 2025. Following this transaction, he directly holds 231,584 shares of Relay Therapeutics common stock, which include 13,075 shares underlying restricted stock units.

Relay Therapeutics, Inc. updated its corporate bylaws to change where certain securities-related lawsuits can be filed. On March 6, 2026, the Board approved second amended and restated bylaws that designate the federal district courts of the United States as the exclusive forum for complaints asserting causes of action under the Securities Act of 1933, the Securities Exchange Act of 1934, or related rules and regulations, unless the company consents in writing to a different forum.

Thomas J. Catinazzo reported sales of company common stock. The filing lists two dispositions: 13,820 shares for $105,308.40 on 01/27/2026 and 1,695 shares for $14,322.75 on 01/28/2026. The record also lists Restricted Stock Units dated 01/27/2025 as securities to be sold.

Relay Therapeutics reported another year of heavy investment in R&D while advancing its precision oncology pipeline. For 2025, the company posted a net loss of $276.5 million, an improvement from $337.7 million in 2024, as research and development expenses fell to $261.4 million from $319.1 million after streamlining programs and transferring FGFR2 asset lirafugratinib to Elevar Therapeutics.

License and other revenue reached $15.4 million, mainly from Elevar milestones, while cash, cash equivalents and investments totaled $554.5 million at year-end. Management believes this liquidity can fund operations into 2029, reducing near-term financing pressure.

Relay’s lead candidate zovegalisib, an allosteric, pan‑mutant, isoform‑selective PI3Kα inhibitor, is in a global Phase 3 breast cancer trial (ReDiscover‑2) and a Phase 1/2 vascular anomalies study. In February 2026, the FDA granted Breakthrough Therapy designation for zovegalisib plus fulvestrant in PIK3CA‑mutant HR+/HER2‑ advanced breast cancer, highlighting the program’s regulatory momentum.

Relay Therapeutics reported narrower losses for 2025 and highlighted key 2026 clinical milestones. Cash, cash equivalents and investments were $554.5 million as of December 31, 2025, compared with $781.3 million a year earlier, and the company expects this cash to fund operations into 2029.

Revenue was $7.0 million in Q4 2025 and $15.4 million for the full year, up from $0 and $10.0 million in 2024, driven by its Elevar license. Research and development expenses fell to $261.4 million for 2025 from $319.1 million, while general and administrative expenses declined to $56.7 million from $76.6 million.

Net loss improved to $54.9 million in Q4 2025, or $0.32 per share, and $276.5 million for the year, or $1.61 per share, versus $76.0 million and $337.7 million in 2024. The company is entering a “pivotal period” in 2026, with initial Phase 1 data for zovegalisib in PIK3CA‑driven vascular anomalies expected in the first half of the year, breast cancer triplet data and frontline Phase 3 plans expected in 2026, and initial Phase 1/2 breast cancer data at the ESMO TAT Congress on March 16, 2026.

Casdin Capital and related entities reported a significant passive stake in Relay Therapeutics, Inc. They disclosed beneficial ownership of 13,003,574 shares of common stock, representing 7.5% of the company. Casdin Partners Master Fund, L.P. directly holds 12,585,000 shares, or 7.3% of the class.

The reporting persons have no sole voting or dispositive power but share voting and dispositive power over these shares. All reported securities are directly owned by advisory clients of Casdin Capital, and the filers certify the holdings are not for the purpose of changing or influencing control of Relay Therapeutics.